EASIGEN-DS: DESIGN STUDY FOR A EUROPEAN INFRASTRUCTURE ON ADVANCED GENOMICS TECHNOLOGIES
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
tramitó un
HORIZON EUROPE:
HORIZON-INFRA-2024-DEV-01
Innovation in the genomics field is extremely intense and requires high up-front investments. The toolbox of sequencing platforms with uniqu...
2024-10-09 - 2028-01-31 | Financiado
2024-10-09 - 2028-01-31 | Financiado
ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2023-DISEASE-07
The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado
2024-08-20 - 2031-08-31 | Financiado
HoloGen: Advancing the development and implementation of hologenomics in biological sciences
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2023-DN-01
Basic biology as well as applied fields such as agrobiology, biomedicine or biotechnology are undergoing a revolution driven by the realisat...
2024-07-09 - 2028-08-31 | Financiado
2024-07-09 - 2028-08-31 | Financiado
RESPIRE-EXCEL: Respiratory Precision Medicine PhD Training Network Excellence through Systems Biology Spatial and...
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
HORIZON EUROPE:
HORIZON-MSCA-2023-DN-01
Asthma and COPD are prevalent, chronic respiratory diseases, with high incidence and societal costs. Current treatment is based on a ‘one-si...
2024-07-01 - 2029-02-28 | Financiado
2024-07-01 - 2029-02-28 | Financiado
BRIDGING-RD: BRIDGing the research and INnovation Gap for Rare Diseases in Europe by upgrading excellence of IMGG...
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
HORIZON EUROPE:
HORIZON-WIDERA-2023-ACCESS-02
There are over 330 million people living on the planet affected by one of over 6,000 identified genetic rare diseases (RD). They urgently ne...
2024-05-13 - 2027-09-30 | Financiado
2024-05-13 - 2027-09-30 | Financiado
CGI-Clinics: Data driven cancer genome interpretation for personalised cancer treatment
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-CARE-05
CGI-Clinics aims at improving personalised medicine in oncology by optimizing genomic data interpretation (after sequencing and before advis...
2022-05-20 - 2027-10-31 | Financiado
2022-05-20 - 2027-10-31 | Financiado
SCREEN4CARE: Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technol...
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
H2020:
H2020-JTI-IMI2-2020-23-two-stage
In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general populat...
2021-10-13 - 2026-09-30 | Financiado
2021-10-13 - 2026-09-30 | Financiado
3D-omics: Three dimensional holo omic landscapes to unveil host microbiota interactions shaping animal product...
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
H2020:
H2020-SFS-2018-2020
Understanding the interplay between animals and microorganisms associated with them has been recognised as an essential step for improving a...
2021-05-10 - 2025-12-31 | Financiado
2021-05-10 - 2025-12-31 | Financiado
GenoMed4ALL: Genomics and Personalized Medicine for all though Artificial Intelligence in Haematological Diseases
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
H2020:
H2020-SC1-FA-DTS-2018-2020
GENOMED4ALL will support the pooling of genomic, clinical data and other -omics health data (data EHR, PET, MRI and CT , Next Generation Se...
2020-12-04 - 2024-12-31 | Financiado
2020-12-04 - 2024-12-31 | Financiado
PROTrEIN: Computational Proteomics Training European Innovative Network
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
H2020:
H2020-MSCA-ITN-2020
PROTrEIN is a Training Network composed of 12 beneficiaries, and 8 partner organizations, from the academic and non-academic sectors with th...
2020-08-18 - 2024-12-31 | Financiado
2020-08-18 - 2024-12-31 | Financiado
3TR: Identification of the Molecular Mechanisms of non response to Treatments Relapses and Remission in...
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
H2020:
H2020-JTI-IMI2-2018-14-two-stage
3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions...
2019-08-22 - 2026-08-31 | Financiado
2019-08-22 - 2026-08-31 | Financiado
IMMUcan: Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
H2020:
H2020-JTI-IMI2-2017-13-two-stage
IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material...
2019-04-23 - 2025-08-31 | Financiado
2019-04-23 - 2025-08-31 | Financiado
BCLLatlas: Single cell genomics to comprehensively understand healthy B cell maturation and transformation to c...
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
tramitó un
H2020:
ERC-2018-SyG
Unbiased analyses of the molecular make up of single cells are revolutionizing our understanding of cell differentiation and cancer. Over th...
2019-03-29 - 2025-12-31 | Financiado
2019-03-29 - 2025-12-31 | Financiado
Solve-RD: Solving the unsolved Rare Diseases
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICO
participó en un
H2020:
H2020-SC1-2016-2017
The main ambitions of the Solve-RD proposal are (i) to solve large numbers of RD, for which a molecular cause is not known yet, by sophistic...
2017-11-27 - 2024-03-31 | Financiado
2017-11-27 - 2024-03-31 | Financiado
* No se disponen de datos de la empresa actual.